GeoVax to Present at BIO International Convention 2022
June 07 2022 - 9:00AM
via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company specializing in developing human vaccines and
cancer immunotherapies, today announced that its Chairman &
CEO, David Dodd, will present at the BIO International Convention
2022 being held June 13-16 in San Diego.
Details of the presentation are as follows:
Date:
June 15, 2022Time:
11:30 a.m. Pacific TimeLocation: San
Diego Convention Center, Company Presentation Theater 4Format:
Company Presentation & One-On-One
MeetingsRegistration: Click Here
During the conference, members of the GeoVax
management team will host one-on-one meetings with registered
attendees to explore collaborative and strategic opportunities
around the company’s development portfolio including GEO-CM04S1, a
multi-antigenic, next generation COVID-19 vaccine currently being
investigated in two Phase 2 studies and Gedeptin®, an
adenovirus-vectored bacterial purine phosphorylase designed to
locally activate a systemically administered chemotherapeutic
prodrug which is currently in a Phase 2 study for the treatment of
advanced Head and Neck (H&N) cancers. Individuals
interested in meeting with GeoVax are encouraged to reach out to
the Company through the scheduling platform available on the
conference website or by contacting Company management
directly.
About GeoVaxGeoVax Labs, Inc. is a
clinical-stage biotechnology company developing human vaccines and
immunotherapies against infectious diseases and cancer using novel
proprietary platforms. GeoVax’s product pipeline includes two
ongoing Phase 2 clinical trials of GEO-CM04S1 (formerly COH04S1)
for COVID-19 as a universal booster vaccine to mRNA vaccines
authorized by the U.S. Food and Drug Administration (FDA) and as a
primary vaccine for use in immunocompromised patients. In addition
to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02 as a
pan-coronavirus vaccine. The Company is also conducting a Phase 1/2
clinical trial of Gedeptin® for treatment of head and neck cancer.
Gedeptin® has been granted orphan drug status by the FDA.
Additional research and development programs include preventive
vaccines against Zika Virus, hemorrhagic fever viruses (Ebola,
Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies
for multiple solid tumors. The Company’s portfolio of wholly owned,
co-owned, and in-licensed intellectual property stands at over 70
granted or pending patent applications spread over 20 patent
families.
For additional information about GeoVax, visit our
website: www.geovax.com.
GeoVax Labs,
Inc.678-384-7220investor@geovax.com
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Sep 2023 to Sep 2024